Precigen (PGEN) Competitors

Edgewise Therapeutics (NASDAQ:EWTX) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Do analysts prefer EWTX or PGEN?

Edgewise Therapeutics presently has a consensus target price of $39.78, indicating a potential upside of 152.56%. Precigen has a consensus target price of $5.50, indicating a potential upside of 266.67%. Given Precigen's stronger consensus rating and higher probable upside, analysts plainly believe Precigen is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Precigen	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in EWTX or PGEN?

Precigen received 397 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. However, 73.21% of users gave Edgewise Therapeutics an outperform vote while only 67.38% of users gave Precigen an outperform vote.

Company	Underperform	Outperform
Edgewise Therapeutics	Outperform Votes 41 73.21%	Underperform Votes 15 26.79%
Precigen	Outperform Votes 438 67.38%	Underperform Votes 212 32.62%

Do insiders and institutionals have more ownership in EWTX or PGEN?

33.5% of Precigen shares are owned by institutional investors. 23.2% of Edgewise Therapeutics shares are owned by company insiders. Comparatively, 47.1% of Precigen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Which has more volatility and risk, EWTX or PGEN?

Edgewise Therapeutics has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, Precigen has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Which has stronger earnings & valuation, EWTX or PGEN?

Precigen has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$100.16M	-$1.55	-10.16
Precigen	$4.20M	105.40	-$95.90M	-$0.56	-2.68

Does the media favor EWTX or PGEN?

In the previous week, Edgewise Therapeutics had 3 more articles in the media than Precigen. MarketBeat recorded 7 mentions for Edgewise Therapeutics and 4 mentions for Precigen. Precigen's average media sentiment score of 1.47 beat Edgewise Therapeutics' score of 0.73 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is EWTX or PGEN more profitable?

Edgewise Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -3,521.68%. Edgewise Therapeutics' return on equity of -26.83% beat Precigen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-26.83%	-25.67%
Precigen	-3,521.68%	-123.06%	-87.33%

Summary

Precigen beats Edgewise Therapeutics on 11 of the 17 factors compared between the two stocks.